Oklahoma Heart Institute performed one of the first procedures in Tulsa using the CardioMEMS ™ HF System (CardioMEMS), a new miniaturized, wireless monitoring sensor to manage heart failure (HF). CardioMEMS is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure.
CardioMEMS features a sensor that is implanted in the pulmonary artery (PA) during a non-surgical procedure to directly measure PA pressure. Increased PA pressures appear before weight and blood pressure changes, which are often used as indirect measures of worsening heart failure. The new system allows patients to transmit daily sensor readings from their homes to their health care providers allowing for personalized and proactive management to reduce the likelihood of hospitalization.
Heart failure occurs when the heart is unable to pump enough blood to meet the body’s demands. According to the American Heart Association, nearly 6 million Americans have heart failure and 900,000 new patients are diagnosed each year. Patients with heart failure are frequently hospitalized, have a reduced quality of life and face a higher risk of death. The Centers for Disease Control and Prevention says that half of heart failure patients die within five years of diagnosis.
The CardioMEMS sensor is designed to last the lifetime of the patient and doesn’t require batteries. Once implanted, the wireless sensor sends pressure readings to an external patient electronic system. There is no pain or sensation for the patient during the readings. CardioMEMS allows the patients to transmit critical information about their heart failure status to a clinician on a regular basis, without the need for additional clinic or hospital visits. This provides clinicians with the ability to detect worsening heart failure sooner and adjust treatment to reduce the likelihood that the patient will need to be hospitalized.
The CardioMEMS HF System, from the global medical device manufacturer Abbott, is approved by the U.S. Food and Drug Administration (FDA) for commercial use in the U.S. For more information, visit //www.heartfailureanswers.com/.
The CardioMEMS sensor is a completely sealed capsule that uses microelectromechanical systems (MEMS) technology. Photo courtesy of Abbott.